Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 856-864

  Boutselis, Irene G ^a   Yu, Xiao ^b   Zhang, Zhong Yin ^b   Borch, Richard F ^a  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUOROMETHYLPHOSPHONATE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; MEMBRANE PERMEABILITY; PH;

CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DIPEPTIDES; HUMANS; INSULIN; MAGNETIC RESONANCE SPECTROSCOPY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHORYLATION; PRODRUGS; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847383241     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061146x     Document Type: Article

References (40)

1. Hunter, T. Signaling-2000 and beyond. Cell 2000, 100, 113-27.
2. Zhang, Z. Y. Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 2001, 5, 416-23.
3. Lund, I. K.; Andersen, H. S.; Iversen, L. F.; Olsen, O. H.; Moller, K. B.; Pedersen, A. K.; Ge, Y.; Holsworth, D. D.; Newman, M. J.; Axe, F. U.; Moller, N. P. Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta. J. Biol. Chem. 2004, 279, 24226-35.
4. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-65.
5. Ventura, J. J.; Nebreda, A. R. Protein kinases and phosphatases as therapeutic targets in cancer. Clin. Trans. Oncol. 2006, 8, 153-60.
6. Goldman, J. M.; Melo, J. V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1084-6.
7. Berman, J.; O'Leary, T. J. Gastrointestinal stromal tumor workshop. Hum. Pathol. 2001, 32, 578-82.
8. Li, L.; Dixon, J. E. Form function and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin. Immunol. 2000, 12, 75-84.
9. Bourdeau, A.; Dube, N.; Tremblay, M. L. Cytoplasmic protein tyrosine phosphatases regulation and function: the roles of PTP1B and TC-PTP. Curr. Opin. Cell Biol. 2005, 17, 203-9.
10. Zhang, Z. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Ann. Rev. Pharmacol. Toxicol. 2002, 42, 209-34.
11. Burke, T. R., Jr; Zhang, Z.-Y. Protein-tyrosine phosphatases: structure mechanism and inhibitor discovery. Biopolymers 1998, 47, 225-41.
12. Zhang, Z.-Y. Inhibitors of protein tyrosine phosphatases. In Handbook of Cell Signaling, 1st ed.; Bradshaw, R.. Dennis, E., Eds; Academic Press: New York, 2003; pp 677-684.
13. Burke, T. R., Jr; Kole, H. K.; Roller, P. P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun. 1994, 204, 129-34.
14. Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. P.; Burke, T. R., Jr; den Hertog, J.; Zhang, Z.-Y. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem. Biophys. Res. Commun. 1995, 216, 976-84.
15. Shen, K.; Keng, Y. F.; Wu, L.; Guo, X. L.; Lawrence, D. S.; Zhang, Z.-Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. 2001, 276, 47311-9.
16. Dufresne, C.; Roy, P.; Wang, Z.; Asante-Appiah, E.; Cromlish, W.; Boie, Y.; Forghani, F.; Desmarais, S.; Wang, Q.; Skorey, K.; Waddleton, D.; Ramachandran, C.; Kennedy, B. P.; Xu, L.; Gordon, R.; Chan, C. C.; Leblanc, Y. The development of potent non-peptidic PTP 1B inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1039-42.
17. Lau, C. K.; Bayly, C. I.; Gauthier, J. Y.; Li, C. S.; Therien, M.; Asante-Appiah, E.; Cromlish, W.; Boie, Y.; Forghani, F.; Desmarais, S.; Wang, Q.; Skorey, K.; Waddleton, D.; Payette, P.; Ramachandran, C.; Kennedy, B. P.; Scapin, G. Structure-based design of a series of potent and selective non-peptidic PTP 1B inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1043-8.
18. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase 1B gene. Science 1999, 283, 1544-8.
19. Klaman, L. D.; Boss, O.; Peroni, O. D.; Kim, J. K.; Martino, J. L.; Zabolotny, J. M.; Moghal, N.; Lubkin, M.; Kim, Y. B.; Sharpe, A. H.; Stricker-Krongrad, A.; Shulman, G. I.; Neel, B. G.; Kahn, B. B. Increased energy expenditure decreased adiposity and tissue-specific insulin sensitivity in protein- -tyrosine phosphatase 1B deficient mice. Mol. Cell Biol. 2000, 20, 5479-89.
20. Zhang, Z.-Y.; Lee, S. Y. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin. Investig. Drugs 2003, 12, 223-33.
21. Xie, L.; Lee, S. Y.; Andersen, J. N.; Waters, S.; Shen, K.; Guo, X. L.; Moller, N. P.; Olefsky, J. M.; Lawrence, D. S.; Zhang, Z.-Y. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 2003, 42, 12792-804.
22. Lee, S. Y.; Liang, F.; Guo, X. L.; Xie, L.; Cahill, S. M.; Blumenstein, M.; Yang, H.; Lawrence, D. S.; Zhang, Z.-Y. Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angew. Chem., Int. Ed. 2005, 44, 4242-4.
23. Liang, F.; Lee, S. Y.; Liang, J.; Lawrence, D. S.; Zhang, Z.-Y. The role of protein-tyrosine phosphatase 1B in integrin signaling. J. Biol. Chem. 2005, 280, 24857-63.
24. Lee, H.; Xie, L.; Luo, Y.; Lee, S. Y.; Lawrence, D. S.; Wang, X. B.; Sotgia, F.; Lisanti, M. P.; Zhang, Z.-Y. Identification of phosphocaveolin-1 as a novel protein-tyrosine phosphatase 1B substrate. Biochemistry 2006, 45, 234-40.
25. Dang, Q. Organophosphonic acids as drug candidates. Expert Opin. Ther. Patents 2006, 16, 343-8.
26. Stankovic, C. J.; Surendran, N.; Lunney, E. A.; Plummer, M. S.; Para, K. S.; Shahripour, A.; Fergus, J. H.; Marks, J. S.; Herrera, R.; Hubbell, S. E.; Humblet, C.; Saltiel, A. R.; Stewart, B. H.; Sawyer, T. K. The role of 4-phosphonodifluoromethyl- and 4-phosphonophenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg. Med. Chem. Lett. 1997, 7, 1904-9.
27. Freel Meyers, C. L.; Hong, L.; Joswig, C.; Borch, R. F. Synthesis and biological activity of novel 5-fluoro-2′-deoxyuridine phosphoramidate prodrugs. J. Med. Chem. 2000, 43, 4313-8.
28. Tobias, S. C.; Borch, R. F. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J. Med. Chem. 2001, 44, 4475-80.
29. Garrido-Hernandez, H.; Moon, K. D.; Geahlen, R. L.; Borch, R. F. Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J. Med. Chem. 2006, 49, 3368-76.
30. Terauchi, K.; Sakurai, H. Photochemical studies of esters of aroylphosphonic acids. Bull. Chem. Soc. Jpn. 1970, 43, 883-90.
31. Burke, T. R.; Smyth, M. S.; Otaka, A.; Roller, P. P. Synthesis of 4-phosphono(difluoromethyl)-D,L-phenylalanine and N-boc and N-fmoc derivatives suitably protected for solid phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues. Tetrahedron Lett. 1993, 34, 4125-8.
32. 2 derivatives. Tetrahedron 1997, 53, 11171-8.
33. Yang, G.; Chun, J.; Arakawa-Uramoto, H.; Wang, X.; Gawinowicz, M. A.; Zhao, K.; Landry, D. W. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. 1996, 118, 5881-90.
34. Namikoshi, M.; Kundu, B.; Rinehart, K. L. Use of tetrabutylammonium fluoride as a facile deprotecting reagent for 4-nitrobenzyl, 2,2,2-trichloroethyl, and phenacyl esters of amino acids. J. Org. Chem. 1991, 56, 5464-6.
35. Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. A mild and selective method for the hydrolysis of esters with trimethyltin hydroxide. Angew. Chem., Int. Ed. 2005, 44, 1378-82.
36. Guo, X. L.; Shen, K.; Wang, F.; Lawrence, D. S.; Zhang, Z.-Y. Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition. J. Biol. Chem. 2002, 277, 41014-22.
37. Sun, J. P.; Fedorov, A. A.; Lee, S. Y.; Guo, X. L.; Shen, K.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J. Biol. Chem. 2003, 278, 12406-14.
38. White, M. F. The IRS-signaling system: a network of docking proteins that mediate insulin action. Mol. Cell Biochem. 1998, 182, 3-11.
39. Saltiel, A. R.; Kahn, C. R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001, 414, 799-806.
40. Clampit, J. E.; Meuth, J. L.; Smith, H. T.; Reilly, R. M.; Jirousek, M. R.; Trevillyan, J. M.; Rondinone, C. M. Reduction of protein-tyrosine phosphatase 1B increases insulin signaling in FAO hepatoma cells. Biochem. Biophys. Res. Commun. 2003, 300, 261-7.